What is Aliqopa (copanlisib)?
Aliqopa (copanlisib) is a kinase inhibitor for the treatment of adults with relapsed follicular lymphoma1.
Who is Aliqopa (copanlisib) for?
Aliqopa (copanlisib) is indicated for the treatment of adult patients who have received at least two prior treatments known as systemic therapies1. Follicular lymphoma is the most common slow-growing form of Non-Hodgkin Lymphoma (NHL), accounting for approximately 12% of all B-cell NHLs2.
How does Aliqopa (copanlisib) work?
Aliqopa (copanlisib) is a ‘tyrosine kinase inhibitor’. This means that it blocks the activity of enzymes known as tyrosine kinases. These enzymes can be found in cancer cells, where they activate several processes including cell division and the growth of new blood vessels to supply the cancer. By blocking the activity of these enzymes in malignant B cells, Aliqopa (copanlisib) reduces the growth and spread of the cancer1.
Where has Aliqopa (copanlisib) been approved?
Aliqopa (copanlisib) was approved for the treatment of patients with relapsed follicular lymphoma by:
Food and Drug Administration (FDA), USA:
September 19, 20171 with an accelerated approval
Please note that this medicine may have also been approved in other regions than the ones we’ve listed. If you have a question about its approval in a specific country feel free to contact our support team.
How is Aliqopa (copanlisib) taken?
The standard dosage is1:
60 mg administered as a 1-hour intravenous infusion on Days 1, 8, and 15 of a 28-day treatment cycle on an intermittent schedule (three weeks on and one week off).
Modify dosage in case of toxicity.
Complete information about Aliqopa (copanlisib) dosage and administration can be found in the official prescribing information listed in our resources section1.
Note: Please consult with your treating doctor for personalised dosing.
Are there any known side effects or adverse reactions of Aliqopa (copanlisib)?
Common adverse reactions
The most common adverse reactions listed in the prescribing information include1:
hyperglycemia (high blood sugar)
diarrhea
decreased general strength and energy
hypertension (high blood pressure)
leukopenia (decreased number of white blood cells (leukocytes))
neutropenia (decreased number of white blood cells (neutrophils))
nausea (feeling sick)
lower respiratory tract infections
thrombocytopenia (decreased number of platelets).
Serious adverse reactions
The serious adverse reactions listed in the prescribing information include1:
infections, including pneumonia
hyperglycemia (high glucose in blood)
hypertension (high blood pressure)
neutropenia (low levels of white blood cells)
severe cutaneous reactions.
Use in specific populations
Aliqopa (copanlisib) can be fatal for a fetus, it is advised to avoid pregnancies and breastfeeding during treatment and for at least one month after the last dose1.
No dose adjustment is necessary in patients above 65 years of age1.
For a comprehensive list of side effects and adverse reactions please refer to the official prescribing information1.
